title: An open-label pilot study of homeopathic treatment of attention deficit hyperactivity disorder in children and youth.
abstract: BACKGROUND
  An open-label pilot study of individualized homeopathy for attention deficit hyperactivity disorder (ADHD) was conducted to assess the potential for future studies with a focus on the feasibility of the recruitment plan and outcome measure schedules; identification of any group characteristics of participants who respond significantly to the therapy; and establishing the length of time required for an improvement in ADHD symptoms.
  
  
  METHODS
  Participants (aged 6-16) were recruited through community advertisement and outreach. Participants completed 1 screening and 9 individualized homeopathic follow-up consultations. ADHD symptoms were assessed using the Conners 3 - Parent Questionnaire administered at each consultation. The pre- and post-study difference in Conners Global Index - Parent (CGI-P) T-score was evaluated for each participant. Baseline data of those who showed a statistically significant improvement (responders) were compared to those who did not (non-responders).
  
  
  RESULTS
  35 participants were enrolled over 11 months. 80% completed all 10 consultations in a median of 12.1 months. 63% had a statistically significant improvement in the primary outcome, first occurring after a mean of 4.5 visits. Overall scores for participants completing at least 2 data points decreased from a baseline median of 85.5 to 74.0 (p < 0.001, CI 95%). There were no significant baseline differences between responders and non-responders. No serious adverse events related to the therapy were reported.
  
  
  CONCLUSIONS
  The change in the median CGI-P T-score from baseline to the end of this open-label pilot study was statistically significant. The research methods are feasible. Future studies are warranted.
  
  
  BACKGROUND
  NCT01141634.
authors.affiliation: University of Toronto, ON, Canada.
authors.forename: David
authors.initials: D
authors.lastname: Brulé
authors.forename: Lauren
authors.initials: L
authors.lastname: Sule
authors.forename: Beth
authors.initials: B
authors.lastname: Landau-Halpern
authors.forename: Violeta
authors.initials: V
authors.lastname: Nastase
authors.forename: Umesh
authors.initials: U
authors.lastname: Jain
authors.forename: Sunita
authors.initials: S
authors.lastname: Vohra
authors.forename: Heather
authors.initials: H
authors.lastname: Boon
mesh_terms: D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000628:therapy*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008419:Materia Medica / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects; D016896:Treatment Outcome
chemical_list: D008419:Materia Medica